"Maximal" thymectomy for myasthenia gravis. Results

Area of Science:

• Neurology
• Surgical Oncology
• Immunology

Background:

• Myasthenia gravis (MG) is a neuromuscular autoimmune disease.
• Thymectomy is a recognized treatment for MG, but optimal surgical technique remains debated.
• Complete thymus removal is crucial due to the thymus's widespread distribution.

Purpose of the Study:

• To evaluate the efficacy of a maximal en bloc transcervical-transsternal thymectomy for generalized myasthenia gravis.
• To compare outcomes based on the presence of thymoma and prior surgical history.

Main Methods:

• Ninety-five patients with generalized MG underwent maximal thymectomy between 1977 and 1985.
• Patients were evaluated for symptom improvement, remission, and outcomes post-surgery.
• Data analyzed for different groups: MG without thymoma, reoperation cases, and MG with thymoma.

Main Results:

• 96% of patients without thymoma benefited, with 79% achieving no symptoms and 46% remission.
• Life table analysis showed an 81% remission rate at 89 months for MG without thymoma.
• Reoperation yielded significant improvement, and patients with thymoma showed a less favorable response compared to those without.

Conclusions:

• Maximal thymectomy is recommended for generalized myasthenia gravis treatment.
• The en bloc transcervical-transsternal approach ensures predictable and complete thymus removal.
• Reoperation with maximal thymectomy is advised for persistent or recurrent severe symptoms.